Dr. J. Francois Eid has performed more internal penile implant surgeries than anyone in the world and has built a reputation for excellence in the treatment of erectile dysfunction (ED). After examining the latest generation of Inflatable Penile Prosthesis (IPP) and Artificial Urinary Sphincter (AUS) technologies from American Medical Systems (AMS) and Coloplast Corporation, reviewing pertinent studies, and drawing on his 20 years of experience performing penile prosthesis surgery and overseeing his patients’ recuperation and subsequent training in operating the devices, Dr. Eid has high praise for the recent improvements. Updates have been made to the IPP pumps offered by both AMS and Coloplast, as well as to the CX and LGX cylinders offered by AMS. Also, AMS has added an antibiotic coating to its AUS.

Momentary Squeeze (MS) Pump - AMS

AMS’s Momentary Squeeze (MS) Pump was first introduced nearly two years ago, and Dr. Eid has implanted it with great success in patients suited to the CX-cylinder and LGX-cylinder versions. (The LGX model offers the potential for increased penile length in patients complaining of penile shortening after radical prostatectomy.) Both cylinders now feature redesigned proximal ends. At only 9.5mm in diameter, the ends allow for significantly easier insertion for patients with fibrotic proximal corporal bodies.

The MS Pump’s advantages include a smaller profile (which enables a more discreet placement) and one-touch deflation. However, this quality can result in operational difficulties with inflation (more difficult to get a hold of within the scrotum) and deflation (small button can initially be difficult to find). In addition, its new lockout valve has the advantage of preventing auto-inflation (potentially embarrassing and/or painful), but can at times make it difficult to initiate inflation. For these reasons, Dr. Eid recommends this pump for the younger patient with an average-sized penis.

Tactile Pump (700 CX Series) - AMS

“The AMS 700 CX Series with the Tactile Pump remains my prosthesis of choice for the older patient where pump concealment is not an issue,” says Dr. Eid. “This pump is large, easily palpable, remains the softest to inflate and has a very large deflation footprint, which is quickly recognized by the patient.” The Tactile pump is not available with the LGX cylinders.

Titan Pump - Coloplast

The FDA approved the improvements to the pump component of the Coloplast Titan prosthesis in July 2008. Although the cylinders and reservoir remain the same as the previous model, the pump now features a one-touch-release (OTR) deflation valve — easy for patients to locate and operable with one hand. In addition, the pump offers a non-bulky, low-profile size; enhanced silicone for higher threshold “tear strength” (likely to result in increased product durability, an issue with previous versions); and an overall simplicity likely to decrease repeat office visits, phone calls, and repeat training time. From a hospital standpoint, intraoperative prep of the device provides for easier priming of the implant system (the removal of excess air prior to filling) and may reduce slightly the overall intraoperative time.

“This remains a great device for the patient with a larger penis,” says Dr. Eid, “as these are the only cylinders that will expand to 22mm girth.” In addition, only Titan cylinders are available in lengths of 24cm, 26cm and 28cm.

Although the pump is easily identified and operated by patients, the small size of the deflation valve sometimes requires a longer learning curve.

In a recent study (”Evaluation of Three Penile Prosthesis Pump Designs in a Blinded Survey of Practitioners,” Urologic Nursing, 2008), 32 medical professionals, all familiar in teaching the operation of penile implants to patients, reviewed currently available penile pumps. The blindfolded reviewers, examining the pumps under time constraints through mock scrotal sacs, were asked to rate device:

– ease of location of deflation valve
– ease of inflation
– ease of deflation, and
– anticipated ability to train patients in clinical setting.

The Titan OTR pump design performed very well and “consistently demonstrated a significant advantage in subject preference.” (Quallich, Ohl & Dunn, 2008, p. 5).

Artificial Urinary Sphincter - AMS

AMS has improved the AUS by coating the device surface with inhibizone. This is the same antibiotic coating (Rifampin and Minocin) currently available on the IPP that has dramatically reduced infection rates since its introduction in 2001. In combination with Dr. Eid’s self-developed “no-touch” surgical technique, which eliminates direct and indirect contact between the prosthesis and the patient’s skin (the origin of most infections), he believes the new coating will offer additional protection against the most common pathogens responsible for sphincter infections.

Dedicated to Patient Education

Dr. Eid has developed a website http://www.UrologicalCare.com dispelling common misconceptions about penile implant surgery. Having performed over 3,000 penile implant surgeries (the most worldwide), Dr. Eid knows what a remarkable and positive difference the treatment can make in a man’s life. Between retaining a normal penis look and feel, employment of multiple techniques for preventing infection, and steady diminishment of pain until it is completely gone within 2-4 weeks, penile implant surgery has proven to be an effective treatment for many men, resulting in normal, healthy and productive lives.

About J. Francois Eid, M.D, and UrologicalCare.com

Dr. Eid is the director and founder of Advanced Urological Care in New York City. He is also a Clinical Associate Professor of Urology at Cornell University. Dr. Eid is one of the foremost specialists in urological prosthetic reconstruction and performs over 300 internal penile implants per year. Dr. Eid leads workshops on penile prosthesis surgeries worldwide. More information about Dr. Eid and his expertise with erectile dysfunction treatment, penile prosthesis implantations and artificial urinary sphincters can be found on his website, http://www.UrologicalCare.com.

UrologicalCare.com

Rexahn Pharmaceuticals, Inc. (NYSE Alternext US: RNN), a leader in development of innovative therapeutics for life-threatening and life-debilitating diseases, announced the completion of enrollment in its Phase IIa clinical trial evaluating ZoraxelTM for treatment of Erectile Dysfunction (ED). The Company expects to have preliminary study results in March 2009.

Zoraxel is being developed as an orally administered tablet for on-demand use, and is one of three compounds being developed by Rexahn as a part of the Company’s clinical stage drug pipeline. In addition to lacking the common side effects associated with many popular ED treatments, Zoraxel has also been shown to significantly improve sexual arousal, erection, and release in disease model studies.

Dr. Chang H. Ahn, Chairman and CEO of Rexahn commented, “It has been our stated goal to move our three highly-marketable compounds successfully through the clinical trial process, and the completion of patient enrollment in the Zoraxel trial represents another steady step in the right direction for Rexahn. This milestone is especially meaningful to us, as we have long believed that our ED compound is a safer and more effective alternative to currently marketed drugs for ED. We look forward to examining and sharing the preliminary data with our shareholders and stakeholders in the near future.”

The Zoraxel Phase IIa trial is a double blind, placebo-controlled, dose ranging study conducted at three U.S. study sites in up to 40 male subjects ages 18 to 65 with ED for six months. Main study endpoints for the 8-week treatment period were the Sexual Encounter Profile (SEP) and the International Index of Erectile Function (IIEF), both of which are validated surveys for assessing erectile function. Planning is underway for initiation of Phase IIb clinical studies.

About ZoraxelTM

ZoraxelTM is being developed as an orally administered, on-demand tablet. It has a well established and excellent safety record in humans and appears to lack severe side effects associated with standard of care phosphodiesterase (PDE-5) inhibitor ED drugs, such as priapism, severe hypotension, myocardial infarction, sudden death, increased intraocular pressure and sudden hearing loss. ZoraxelTM is a centrally acting, dual enhancer of neurotransmitters in the brain, whereas PDE-5 inhibitors only target end organ erectile function and work in peripheral blood vessels. In preclinical animal models, ZoraxelTM has significantly improved all three functions of sexual activity, i.e. sexual arousal, erection, and release, and may be a more effective ED treatment for patients who are responsive or unresponsive to PDE-5 inhibitors.

About Erectile Dysfunction (ED)

ED is defined as the consistent inability to attain and maintain an erection sufficient for satisfactory sexual intercourse. ED affects up to 30 million estimated men in the United States, with 52% of men between the ages of 40 and 70 reporting difficulty with erectile function. By the year 2025, it is estimated that 322 million men worldwide will suffer from some degree of sexual dysfunction.

About Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals is a clinical stage pharmaceutical company dedicated to commercializing first in class and market leading therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs. For more information please visit http://www.rexahn.com

Safe Harbor

This press release contains forward-looking statements. Rexahn’s actual results may differ materially from anticipated results, and expectations expressed in these forward-looking statements, as a result of certain risks and uncertainties, including Rexahn’s lack of profitability, its auditor’s going concern qualification and the need for additional capital to operate its business to develop its product candidates; the risk that Rexahn’s development efforts relating to its product candidates may not be successful; the possibility of being unable to obtain regulatory approval of Rexahn’s product candidates; the risk that the results of clinical trials may not be completed on time or support Rexahn’s claims; demand for and market acceptance of Rexahn’s drug candidates; Rexahn’s reliance on third party researchers and manufacturers to develop its product candidates; Rexahn’s ability to develop and obtain protection of its intellectual property; and other risk factors set forth from time to time in our filings with the Securities and Exchange Commission. Rexahn assumes no obligation to update these forward-looking statements.

Rexahn Pharmaceuticals, Inc.